BTIG Research reaffirmed their neutral rating on shares of Insight Molecular Diagnostics (NASDAQ:IMDX – Free Report) in a research report sent to investors on Wednesday morning, MarketBeat.com reports.
IMDX has been the subject of several other reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Insight Molecular Diagnostics in a research note on Monday, September 21st. Wall Street Zen lowered shares of Insight Molecular Diagnostics from a “hold” rating to a “sell” rating in a report on Saturday, October 3rd. Needham & Company LLC restated a “buy” rating and set a $9.00 price objective on shares of Insight Molecular Diagnostics in a research report on Tuesday, August 18th. Finally, Stephens reaffirmed an “equal weight” rating and set a $4.00 price objective on shares of Insight Molecular Diagnostics in a report on Wednesday. Two analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $5.75.
Read Our Latest Stock Report on IMDX
Insight Molecular Diagnostics Stock Up 17.5%
Insight Molecular Diagnostics (NASDAQ:IMDX – Get Free Report) last released its quarterly earnings results on Monday, November 16th. The company reported ($0.19) earnings per share for the quarter. The company had revenue of $0.56 million during the quarter.
Insider Activity at Insight Molecular Diagnostics
In other news, major shareholder Broadwood Partners, L.P. purchased 3,428,571 shares of the company’s stock in a transaction that occurred on Tuesday, November 17th. The stock was purchased at an average cost of $1.75 per share, for a total transaction of $5,999,999.25. Following the completion of the transaction, the insider owned 16,113,455 shares of the company’s stock, valued at $28,198,546.25. This trade represents a 27.03% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through the SEC website. Insiders own 2.21% of the company’s stock.
Insight Molecular Diagnostics Company Profile
Oncocyte Corporation, now known as Insight Molecular Diagnostics, Inc. (NASDAQ: IMDX), is a molecular diagnostics company focused on monitoring organ transplants. Its tests analyze donor-derived cell-free DNA in a transplant recipient’s blood to help assess graft health and identify signs of potential injury or rejection. The company’s VitaGraft tests include assays for kidney and liver transplant monitoring. These laboratory-developed tests are processed through the company’s clinical laboratory and are intended to provide clinicians with information that can complement other aspects of post-transplant care.
Further Reading
- Five stocks we like better than Insight Molecular Diagnostics
- Survey Reveals: How Much Would People Pay for Ribeye Before Giving It Up? [2026]
- If NVIDIA Tightens Its Wallet, These 3 Stocks Could Feel It
- 3 Dividend ETFs Offering Steadier Footing in a Shaky Market
- Lazard’s New ETF Targets Monthly Income With Junk Bonds
Receive News & Ratings for Insight Molecular Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insight Molecular Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.
